Evaluation Of Capecitabine In Patients With Platinum-Pretreated Advanced Or Recurrent Cervical Carcinoma: A Retrospective Study Of The Irccs National Cancer Institute Of Milan

5535Background: Cervical cancer is underrepresented in the gynecological clinical research. The objective of this retrospective study was to evaluate the activity and the safety of capecitabine in patients with platinum-pretreated recurrent cervical carcinoma. Methods: We performed a retrospective review of medical records from patients with advanced or recurrent cervical carcinoma pretreated with platinum-based therapy who received oral capecitabine at the Gynecological Units of the IRCCS National Cancer Institute of Milan (Italy). We used Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 to evaluate response to therapy and Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to evaluate adverse events. Results: From October 2013 to August 2017, we treated with oral capecitabine dose 29 patients with advanced or recurrence cervical carcinoma, already exposed to platinum. All patients receive a combination of carboplatin plus paclitaxel as first-line therapy for advanced/recu...